CLINICAL TRIALS PROFILE FOR TREMFYA

All Clinical Trials for TREMFYA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03079531 ↗	Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea	Completed	Anne Chang	Phase 1/Phase 2	2017-06-21	This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.
NCT03649971 ↗	A Study of Guselkumab in Participants With Familial Adenomatous Polyposis	Active, not recruiting	Janssen Research & Development, LLC	Phase 1	2018-11-19	The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
NCT03818035 ↗	A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis	Active, not recruiting	Janssen-Cilag G.m.b.H	Phase 3	2019-02-08	The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).
NCT04340076 ↗	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis	Recruiting	Belgium Health Care Knowledge Centre	Phase 4	2020-08-20	The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.
NCT04340076 ↗	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis	Recruiting	University Hospital, Ghent	Phase 4	2020-08-20	The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.
NCT04340076 ↗	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis	Recruiting	ZonMw: The Netherlands Organisation for Health Research and Development	Phase 4	2020-08-20	The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.

Clinical Trial Conditions for TREMFYA

Condition Name

Condition Name for TREMFYA
Intervention	Trials
Arthritis, Psoriatic	4
Psoriasis	3
Plaque Psoriasis	2
Psoriatic Arthritis	2

Condition MeSH

Condition MeSH for TREMFYA
Intervention	Trials
Arthritis, Psoriatic	6
Arthritis	6
Psoriasis	6
Nasopharyngeal Neoplasms	1

Clinical Trial Locations for TREMFYA

Trials by Country

Trials by Country for TREMFYA
Location	Trials
United States	72
Canada	8
Poland	6
Spain	5
Ukraine	4

Trials by US State

Trials by US State for TREMFYA
Location	Trials
Texas	6
California	6
Ohio	5
New York	5
Florida	5

Clinical Trial Progress for TREMFYA

Clinical Trial Phase

Clinical Trial Phase for TREMFYA
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	7
Phase 2	2

Clinical Trial Status

Clinical Trial Status for TREMFYA
Clinical Trial Phase	Trials
Recruiting	7
Not yet recruiting	6
Active, not recruiting	2

Clinical Trial Sponsors for TREMFYA

Sponsor Name

Sponsor Name for TREMFYA
Sponsor	Trials
Janssen Research & Development, LLC	10
Janssen Scientific Affairs, LLC	2
University of Pennsylvania	2

Sponsor Type

Sponsor Type for TREMFYA
Sponsor	Trials
Industry	14
Other	8